Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifirafenib in solid tumors
NCT02610361Phase 1Completed
- Sponsor
- BeiGene
- Start
- Nov 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of lifirafenib in solid tumor, sponsored by BeiGene. Primary endpoints: Number of participants with adverse events and Objective Response Rate. Started Nov 2013; status: completed.
02
Drugs
lifirafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02610361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610361.